AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
A failed trial is a failed trial, says China’s regulator
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
